Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by retiredcopon Dec 01, 2020 12:50am
650 Views
Post# 32007213

Blood test for dementia

Blood test for dementiahttps://www.nbcnews.com/health/aging/first-blood-test-help-diagnose-alzheimer-s-goes-sale-n1249355

Great if it their test works because now PMN has something to compare its AD blood test when its done. 

A couple of red flags popped up when I was reading this article ( the last section "does it work"  They have not published any of their supporting data for other sceintists to review and see if it actually is doing what they said. They are applying to the FDA for fast track approval and want to start selling it right now because they say there is such a need... except THERE IS NO TREATMENT.  Hope to see more updates on this as it goes through the review process.

Also wonder if the timing of this and the urgency attempt to put pressure on the FDA to approve Biogen's drug.  Treatment and diagnosis now work hand in hand. More questions then answers right now.    
<< Previous
Bullboard Posts
Next >>